Biotech and pharma social teams are stuck between legal review that kills anything interesting and a scientific audience that ignores anything generic. We build a social strategy that clears review before it is posted and still says something worth reading.
The Problem
Legal review strips out anything that would actually get attention
Every claim in a biotech or pharma social post can trigger a regulatory review cycle, so most teams default to safe, generic language to avoid the back-and-forth. The result is a feed full of stock photography and vague statements about innovation that neither scientists nor investors engage with, while competitors who invested in a pre-cleared claims process post real substance and win the attention.
Three audiences need the platform at once and get one feed
A biotech company's social presence has to speak to potential investors watching for pipeline news, scientists evaluating technical credibility, and sometimes patients or caregivers looking for hope and clarity. Most teams run a single generic feed that serves none of these audiences well, because building distinct content tracks feels like more work than the team has bandwidth for.
Organic reach is near zero without a distribution plan
Biotech and pharma social accounts often post into a vacuum – a handful of employees liking the post and nothing else. Without a deliberate plan for who amplifies content, which platforms actually reach the scientific and investor community, and how paid support fills the gap, even good content never reaches the people it was written for.
Crisis moments catch teams with no playbook
Clinical trial news, regulatory setbacks, or a competitor's announcement can shift the narrative around your company overnight. Teams without a pre-built response framework either go silent, which reads as evasive, or scramble to draft a response through legal in real time, which is far too slow for how fast social conversation moves.
How We Help
Assessment starts with an audit of what is currently posted, what gets engagement, and where the legal review process is actually slowing things down versus where the team is just avoiding the conversation. We pull competitor social activity too, because most biotech and pharma teams have not looked closely at how their peers are handling the same review constraints and still posting substantive content.
Strategy development splits the audience into distinct tracks. Investor-facing content covers pipeline milestones, leadership visibility, and conference presence, timed around actual news rather than a generic content calendar. Scientific-audience content goes deeper on methodology, publications, and technical credibility, built for platforms where researchers actually spend time. Patient or caregiver content, where relevant, gets handled with a different tone entirely, focused on clarity and honesty rather than promotional language.
Execution includes building a pre-cleared claims library with legal, so posts do not each require a fresh review cycle – the language has already been approved for the specific claim categories the company makes most often. We also build the crisis response framework in advance: pre-approved holding statements, an escalation path, and a decision tree for who signs off on what, so a real event does not turn into a scramble.
Measurement tracks engagement by audience segment, not a single blended number that hides whether investors, scientists, or patients are actually responding. We report on what is working by content type and adjust the mix monthly rather than running the same content plan for a year regardless of results.
What we deliver
- Pre-cleared claims library – approved language for the claim categories your team posts about most, cutting review time on future posts
- Audience-segmented content calendar – separate tracks for investor, scientific, and patient or caregiver audiences
- Crisis response framework – pre-approved holding statements and a clear escalation path for fast-moving news
- Distribution plan – paid support and internal amplification mapped to where each audience actually spends time
Biotech and pharma social teams do not have a content problem. They have a review-speed problem. Fix the review process with a pre-cleared claims library and the content gets better on its own because the team stops writing to avoid a fight with legal.
Our Methodology
Our 90-day social strategy sprint starts with a full audit of current content, engagement data, and the legal review workflow itself – not just what gets posted, but how long it takes to get approved and where the process breaks down. This produces a clear picture of whether the bottleneck is creative, process, or both.
Days 30 to 60 build the pre-cleared claims library alongside legal and regulatory reviewers, along with the audience-segmented content calendar and the crisis response framework. Days 60 to 90 move into execution and measurement – publishing against the new calendar, tracking engagement by audience segment, and refining the claims library based on what legal actually flags versus approves without issue.
What makes this different from a standard social media engagement is that the process work happens before the creative work. A brilliant content calendar is useless if every post still takes three weeks to clear legal, so we fix the bottleneck first and build the content strategy on top of a review process that can actually keep pace.
How We Work
The first 30 days run close with your marketing and legal teams to complete the audit and build the pre-cleared claims library – typically 2-3 days a week. Days 30 to 90 shift to content production and publishing cadence, usually 1-2 days a week plus ongoing content review support.
You provide access to current social accounts, analytics, and time with your legal or regulatory reviewer during the claims library build. We handle strategy, content calendar development, and measurement. Content creation can run through our team, yours, or a hybrid depending on internal capacity.
Weekly working sessions review the content pipeline and any claims that need fresh legal sign-off. Monthly reviews cover engagement by audience segment and adjust the content mix. Most engagements run 4-6 months for the initial build, with an ongoing retainer for content production and crisis-readiness maintenance.
- Faster legal review turnaround on social content
- Engagement growth segmented by investor, scientific, and patient audiences
- A tested crisis response framework ready before it is needed
If your biotech & pharma company needs social media strategy leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does social media strategy cost for a biotech or pharma company?
Strategy and claims library development typically runs $8K to $18K per month, with ongoing content production as a separate line depending on volume and whether it runs through our team or yours. Companies with an existing but slow-moving legal review process see the fastest ROI because the claims library work removes the biggest bottleneck immediately.
How long before we see results from a social media strategy engagement?
The claims library and audience-segmented calendar are typically ready within 45-60 days. Engagement improvements usually show up within the first two months of publishing against the new plan, since most of the gain comes from posting substantive content faster rather than waiting on a slow legal cycle. Investor and scientific audience growth compounds over 3-6 months.
How does the social media team integrate with our existing staff?
We work directly with your marketing team and legal or regulatory reviewer, particularly during the claims library build where getting the process right matters more than the content itself. Your team retains ownership of the accounts and final publishing decisions – we build the strategy, calendar, and pre-cleared content, and support execution.
What makes Winston Francois different from a typical social media agency?
Most social agencies treat legal review as someone else's problem and hand off content that then sits in a queue for weeks. We build the pre-cleared claims process as part of the engagement, which is usually the single biggest reason biotech and pharma social feeds go stale. We also segment content by audience instead of running one generic feed for investors, scientists, and patients alike.
How do you measure ROI from a social media strategy investment?
We track engagement by audience segment – investor, scientific, and patient or caregiver – rather than a single blended metric that hides which audience is actually responding. We also track review turnaround time as a direct measure of whether the claims library is working. Most engagements need 3-4 months before the full pattern is clear.
What type of biotech or pharma company is the right fit for this service?
Companies with an active social presence that has gone stale due to slow legal review, or companies about to scale investor and public visibility ahead of a raise or milestone announcement. The best fit is a team that recognizes the review process is the real bottleneck, not a team looking for a content calendar alone.
